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Background: Concurrent chemotherapy and radiation therapy is the preferred standard of care for patients with
anal cancer. Several studies have suggested a benefit of intensity-modulated radiation therapy (IMRT) compared
with 3D-conformal radiation (3D-CRT) regarding acute toxicity. This study evaluates outcome and toxicity of patients
undergoing IMRT/Tomotherapy or 3D-CRT at our institution.
Methods: A cohort of 105 anal cancer patients was treated with chemoradiation or radiation alone (16.2%)
between January 2000 and December 2011. 37 patients received 3D-CRT while 68 patients were treated with IMRT.
Follow-up exams were performed every 3 to 6 months for a minimum of 3 years and then annually.
Results: Median follow-up was 41.4 months (2.8 – 158.4). Overall survival (OS), Progression-free survival (PFS)
and local control (LC) at 3 years was 70.3%, 66.5%, 78.3% in the 3D-CRT group and 82.9%, 66.5%, 75.3% in the
IMRT group without statistically significant difference. 3-year Colostomy-free survival (CFS) was 85.7% in the
IMRT/Tomotherapy group and 91.8% in the 3D-CRT group (p = 0.48). No grade 4 toxicity was found in both groups.
Severe (G2/3) acute skin toxicity (94.6% vs. 63.2%; p < 0.001) and acute gastrointestinal toxicity rate (67.6% vs. 47.1%;
p = 0.03) was significantly higher with 3D-CRT compared to IMRT/Tomotherapy.
Conclusion: The use of IMRT can reduce acute severe side effects of the skin and gastrointestinal tract but did not
demonstrate improved results regarding OS, PFS, LC and CFS.
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With age-standardised incidence rates between 1 and 2
per 100000 per year anal cancer is the less frequent GI
tumours, but several studies have shown an increasing
incidence over the past years [1-4]. The long-term up-
date of the Radiation Therapy Oncology Group (RTOG)
98–11 trial confirmed the established concurrent che-
moradiation (CCR) with 5-fluorouracil (5-FU) plus mito-
mycin (MMC) as the preferred standard of care. The
5 year disease-free survival (DFS) of 67.8% and 5 year
overall survival (OS) of 78.3% were achieved at the cost
of a high incidence of grade 3 and 4 toxicity [5]. These
side effects were in part attributed to the use of older* Correspondence: Stefan.Koerber@med.uni-heidelberg.de
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unless otherwise stated.radiation techniques (RT) such as nonconformal AP/PA
radiotherapy, which leads to a high dose exposure in
normal tissues such as genitalia or small bowel. Today,
many oncological centres use modern techniques like
step-and-shoot intensity-modulated radiation therapy
(IMRT) or Tomotherapy, as recommended by the Na-
tional Comprehensive Cancer Network (NCCN), for the
treatment of patients with anal cancer [6]. A couple of
institutions reported, that treatment-related side effects
could be dramatically reduced while receiving a good
outcome using IMRT for anal cancer [7,8].
At the department of radiation oncology, University
Hospital Heidelberg, and at the department of radiation
oncology at the German Cancer Research Center, Heidel-
berg, IMRT for radiation therapy for anal cancer patients
was introduced during 2003–2004. This retrospective
analysis reports on the efficacy and toxicity of anal cancerl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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or IMRT/Tomotherapy at our institution.
Methods
Patient and tumor characteristics
From January 2000 to December 2011 a total of 105 anal
cancer patients were treated with radiotherapy or radio-
chemotherapy at the department of radiation oncology,
Heidelberg. Patient and tumour characteristics are shown
in Table 1. 37 patients with a median age of 61.0 years
(range 35 – 94 years) received a 3D-CRT while 68 pa-
tients with a median age of 54 years (range 22 – 86 years)
were treated with IMRT/Tomotherapy. Women were af-
fected more frequently than men (80.9% vs. 19.1% in the
IMRT/Tomotherapy group; 97.3% vs. 2.7% in the 3D-
CRT group). In the majority of cases histological examin-
ation showed squamous cell carcinoma. About 50% of
the patients had a tumour size from 2 – 5 cm, typically
without any distant metastases (97.1% vs. 100%). 13 pa-
tients (35.1%) of the 3D-CRT group and 12 patients
(17.6%) of the IMRT/Tomotherapy group underwent
local excision before chemoradiation (Rx: 16%; R0: 16%;
R1: 60%; R2: 8%). 21.6% in the 3D-CRT group and 5.9%Table 1 Patient and tumour characteristics according to
the type of radiotherapy (3D-CRT vs. IMRT/Tomotherapy)
3D-CRT IMRT/Tomotherapy
Total number of patients 37 (35.2%) 68 (64.8%)
Age [years]
Median 61 54
Range 35 - 94 22 - 86
Sex
Male 1 (2.7%) 13 (19.1%)
Female 36 (97.3%) 55 (80.9%)
T stage
T1 9 (24.3%) 11 (16.2%)
T2 18 (48.7%) 36 (52.9%)
T3 6 (16.2%) 13 (19.1%)
T4 4 (10.8%) 8 (11.8%)
N stage
N0 29 (78.4%) 50 (73.5%)
N1 1 (2.7%) 8 (11.8%)
N2 5 (13.5%) 4 (5.9%)
N3 2 (5.4%) 6 (8.8%)
M stage
M0 37 (100%) 66 (97.1%)
M1 0 (0%) 2 (2.9%)
Histology
Squamous cell 35 (94.6%) 65 (95.6%)
Other (small cell, basaloid) 2 (5.4%) 3 (4.4%)in the IMRT/Tomotherapy group received colostomies
immediately following the initial diagnosis before starting
chemoradiation (time range: 0.1 – 2.6 months). The most
common indications for colostomy included protective
reasons and clinically manifest subileus.
Radiochemotherapy
Patients were simulated in supine position before radio-
therapy using CT-scans and knee support for immobilisa-
tion. 3D-CRT was performed using a standard three- to
five-field box including the pelvis from promontorium to
the perianal region. The first radiation sequence (median
45.0 Gray (Gy); range 36.0 – 50.4 Gy) involved the
macroscopic tumour, bilateral iliac, inguinal and pararec-
tal lymph nodes. For the second radiation sequence (to a
median cumulative dose 54.0 Gy; range 45.0 – 61.1 Gy)
the volume was radically reduced to include the macro-
scopic tumour and the involved lymph nodes. For super-
ficial lesions an additional boost with electrons was
performed (35.1%). 14 patients received a boost with
electrons and photons, the other patients (10; 27.0%) re-
ceived only a photon boost. Daily fraction dose was
1.8 Gy in the first and second radiaton sequence. For
IMRT/Tomotherapy anatomical structures and target
volumes were countoured based on MRI and CT images.
Gross tumour volume (GTV) was defined as visible
tumour mass or involved node(s) on imaging. Elective
nodal volumes including mesorectum, presacral space,
ischiorectal fossa, inguinal/obturator/iliac (internal and
external) lymph nodes were contoured. By combining
GTV, the complete anal canal and both anal sphincters
with 20 mm margins the clinical target volume (CTV)
was obtained. For planning target volume (PTV) CTV
was enlarged by 10 mm (Figure 1). IMRT/Tomotherapy
was performed using daily image guidance. Median radi-
ation dose of elective nodes was 45.0 Gy (range 36.0 –
50.4 Gy). Radiotherapy delivered a dose of up to 63.2 Gy
with a median dose of 54.5 Gy to gross tumour and in-
volved nodes by using simultaneous integrated boost
technique. Radiotherapy was done five days a week (once
daily) in 1.8 Gy/2.2 Gy daily fractions respectively.
During chemoradiation women received vaginal tam-
pons and cones to spare the anterior vaginal wall. Vaginal
dilators were offered women after therapy to prevent vagi-
nal stenosis. Of the 105 patients, 79 received concomitant
radiochemotherapy with 5-fluorouracil 1000 mg/m2 body
surface (typically days 1–5 and 29–33) plus mitomycin
10 mg/m2 body surface (days 1 and 29). A discontinuation
of therapy after the first chemotherapy cycle was necessary
because of fulminant side effects (e.g. thrombocytopenia)
for 9 patients. 3 patients obtained only 5-FU and 2 cis-
platin plus 5-FU. Patients with relevant comorbidities
(e.g. cardiac conditions) and/or poor Karnofsky perform-
ance score (16) received only radiotherapy, 5 patients
Figure 1 Dose distribution on planning CT with 3D-CRT and IMRT for a patient with anal cancer [from left to right].
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setting.Clinical course and follow-up
During therapy patients were examined at least once a
week (including blood tests and physical examination).
After radiotherapy or radiochemotherapy follow-up exams
were performed every 3 to 6 months for a minimum of
3 years and then annually. Routine follow-up consisted of
physical examination, imaging (MRI or CT), rectoscopy
and biopsy for abnormal findings. Treatment response
was determined based upon Response Evaluation Criteria
In Solid Tumours (RECIST), version 1.1. Acute and long-
term side effects were scored according to Common Ter-
minology Criteria for Adverse Effects (CTCAE), version
4.0. Late toxicity was defined as adverse effects apparent
6 months after therapy.Statistical analysis
All survival end points were calculated starting from the
first diagnosis date. OS was then defined as the time to
death. LC was defined as the time to locally progressive
disease of the primary tumour or regional lymph nodes.
PFS and CFS were defined as the time to progressive dis-
ease/time to colostomy or death. All patients who did not
experience the event of interest were censored at the last
follow-up date. The Kaplan-Meier method was utilized to
estimate OS, PFS, CFS and LC for various group parti-
tions. Univariate survival time comparisons were per-
formed using the log-rank test. Multivariate analyses,
where possible, were performed using Cox regression.
Univariate analysis of acute toxicity in the 3D-CRT and
IMRT/Tomotherapy groups was performed using the
exact Fisher test. The statistical analysis was performedusing R version 3.0.2. This retrospective analysis was ap-
proved by local ethics committee Heidelberg.
Results
The cohort of 105 patients treated by IMRT/Tomotherapy
or 3D-CRT showed no significant differences regarding
patient and tumour characteristics except for a higher
proportion of women in the 3D-CRT group.
Tumour response and outcome
Median follow-up for the whole cohort was 41.4 months
(2.8 - 158.4), for the 3D-CRT group 97.5 months and for
the IMRT group 30.8 months. Concerning the follow-up
examination imaging showed 64 (60.9%) complete remis-
sions (CR), 5 (4.8%) partial remissions (PR) and 5 (4.8%)
patients with stable disease (SD) in both treatment groups.
12 patients in the 3D-CRT group and 21 patients in the
IMRT/Tomotherapy group (total 33, 31.4%) developed
progressive disease (PD), 8/13 of them a local progression.
3/7 patients relapsed with distant metastases, 1/1 pre-
sented with systemic and local relapse. In these cases pa-
tients underwent further therapy, e.g. abdominoperineal
resection or palliative chemotherapy. One patient was lost
to follow-up, one patient died during chemoradiation be-
cause of an unknown Fanconi anaemia. The 2-year and 3-
year OS for the whole cohort was 86.0% and 77.4% re-
spectively. Regarding the two different radiation therapy
groups, OS rate at 2 and 3 years was 83.8% and 70.3% in
the 3D-CRT group and 87.4% and 82.9% in the IMRT/
Tomotherapy group (Figure 2). There was a trend towards
better survival in patients treated with IMRT/Tomother-
apy, although this difference was not statistically signifi-
cant (p = 0.07). Subgroup analysis of the entire cohort
regarding gender and age showed a 2-year OS of 63.5%
for male and 89.5% for female patients (p = 0.05) and a
Figure 2 Kaplan-Meier estimates of OS and LC for 3D-CRT and IMRT/Tomotherapy group [from left to right].
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60 years (91.4% vs. 79.0%; p = 0.03) (Figure 3).
PFS rate at 2/3 years was 73.3%/66.5%, respectively. 2-
and 3-year PFS rates of 72.9%/66.5% and 73.3%/66.5%
were observed in the 3D-CRT and IMRT/Tomotherapy
group (p = 0.88). 2- and 3-year LC showed no statisti-
cally significant difference between the two radiation
therapy groups (p > 0.99), with a 78.3%/78.3% rate vs.
83.0%/75.3% rate in the 3D-CRT and IMRT/Tomother-
apy group. CFS rate at 2 and 3 years was 89.6% and
87.9% for the whole cohort, 91.8%/91.8% in the 3D-CRT
group and 88.6%/85.7% in the IMRT/Tomotherapy
group (p = 0.48).
Subgroup analysis for different treatment groups
Subgroup analysis was performed for all 79 patients re-
ceiving standard chemoradiation with 5-fluorouracil and
mitomycin. No statistically significant difference could
be found regarding OS and CFS for the 3D-CRT andFigure 3 Kaplan-Meier estimates of OS according to gender and ageIMRT/Tomotherapy group (p = 0.15 and p = 0.33) with
2-year OS rates of 87.5% vs. 90.1%. Despite an estimated
3-year PFS of 77.3% (3D-CRT) vs. 69.9% (IMRT/
Tomotherapy) the values did not reach statistical differ-
ence (p = 0.36; Figure 4). A total of 20 patients (25.3%)
developed progressive disease in this cohort (Table 2). 11
patients (13.9%) relapsed locally or within the regional
lymph nodes whereas most of these recurrences occurred
infield (90.0%). Systemic relapse was observed in 7 pa-
tients (8.9%), two patients developed local and systemic
relapse. In most cases distant metastases occurred in liver
or lung. There was no statistical difference in local or sys-
temic relapse regarding both treatment groups (3D-CRT
vs. IMRT/Tomotherapy). Median OS and PFS for the co-
hort of patients (5) receiving radiation and cetuximab
were 26.8 and 15.5 months. Progressive disease was ob-
served in 2 patients (40%). One patient developed local
recurrence (infield), liver metastases occured in the other
patient.(cut-off 60 years) [from left to right].
Figure 4 Kaplan-Meier estimates of LC in the standard
chemoradiation group for 3D-CRT and IMRT/Tomotherapy.
Koerber et al. Radiation Oncology 2014, 9:113 Page 5 of 8
http://www.ro-journal.com/content/9/1/113Anal cancer was situated at the anal margin in five pa-
tients. One patient died during chemoradiation (unknown
Fanconi anaemia), two patients were treated with radio-
therapy alone. Median OS and PFS for this group were
24.1 and 15.7 months. Local recurrence was observed in
two patients (50%) localized as an infield relapse.
Influence on OS, PFS and LC
Different tumour and treatment characteristics (T-stage,
technique of radiotherapy and concurrent chemotherapy)
were tested as predictive factors in multivariate analysis.
Tumour size (p = 0.04) and the use of chemotherapy (p =
0.03) had a significant influence on OS. For PFS and LC,
only tumour size was a predictive factor (p = 0.03/0.004).
Acute and late toxicity
In both therapy groups, no high-grade adverse events
(G4) were found both for acute and late toxicity. No or
minimal symptoms (G0/1) on the one hand, moderate
and severe symptoms (G2/3) on the other hand were sum-
marized according to limitation of Activities of Daily Liv-
ing (ADL). Acute and late toxicity are listed in Table 3.Table 2 Patterns of recurrence according to the type of
radiotherapy (3D-CRT vs. IMRT/Tomotherapy)
3D-CRT IMRT/Tomotherapy
Total number of patients 24 55
Progressive disease (PD) 5 (20.8%) 15 (27.3%)
Local recurrence 2 (8.3%) 9 (16.4%)
Infield 2 (8.3%) 8 (14.6%)
Outfield 0 1 (1.8%)
Systemic relapse 2 (8.3%) 5 (9.1%)
Local and systemic relapse 1 (4.2%) 1 (1.8%)94.6% of 3D-CRT patients and 63.2% of IMRT/Tomother-
apy patients experienced acute severe (G2/3) dermatologic
toxicity (p < 0.001). The rate of acute severe toxicity of the
gastrointestinal tract was 67.6% in the 3D-CRT group and
47.1% in the IMRT/Tomotherapy group (p = 0.03). Severe
colpitis and dysuria occurred in 27% vs. 25% and 21.6% vs.
19.1% (3D-CRT vs. IMRT/Tomotherapy group) - without
statistically significant differences between the considered
two groups. G2 and G3 chronic toxicitiy regarding dysuria
was observed for only 1 (2.7%) vs. 2 (2.9%) patients (3D-
CRT vs. IMRT/Tomotherapy) undergoing chemoradia-
tion. The rate of severe atrophy of vaginal mucosa was
16.2% in both treatment groups. A total of 4 (3.8%) pa-
tients developed faecal incontinence after chemoradiation,
2 (5.4%) in the 3D-CRT group (G2: 2 patients), 2 (2.9%) in
the IMRT/Tomotherapy group (G1: 2 patients). Male pa-
tients didn’t develop G2 or G3 toxicity regarding potency.
In all cases multivariate analysis has not been performed
due to the small number of events.
Discussion
For many years radiotherapy plus chemotherapy (5-FU
and MMC) has represented the international standard of
care for patients with anal carcinoma [9-11]. This leading
treatment role has been confirmed by a 13-year follow-
up showing only a small proportion of localregional re-
lapse and cancer deaths undergoing a radiochemotherapy
compared with RT alone [12]. Several studies suggest an
equivalent if not better outcome with decreased toxicity
by modern radiation techniques such as IMRT when
compared to 3D-CRT [8,13,14]. The present analysis
studied a large cohort of 105 patients with anal cancer
treated with radiation therapy or chemoradiation at the
department of radiation oncology, University Hospital
Heidelberg and at the department of radiation oncology
at the German Cancer Research Center, Heidelberg. The
3-year OS rate of 77.4% in our cohort was similar to that
seen in comparable studies such as Bazan et al. with
72.0% [13]. Regarding 3D-CRT Dewas et al. reported an
81.1% 2-year OS [15] which is consistent with the 2-year
OS rate of our cohort of 83.8%. In the present study 2-
year OS of the IMRT/Tomotherapy group was 87.4%, re-
spectively. Findings from other studies on IMRT showed
2-year OS ranging from 86.9% to 96.0% [15-17]. Even if
no statistically significant overall survival difference be-
tween the two radiation technique groups was found (p
= 0.07) as reported by Bazan et al. (3-year OS 88% vs.
52%; p < 0.01) [13], there seems to be a trend favoring
IMRT/Tomotherapy. The lower OS in the 3D-CRT group
observed in our study is multifactorial and could be ex-
plained by a tendency to an older population in the 3D-
CRT cohort (median age 61 years vs. 54 years, p > 0.05).
This fact and the associated larger proportion of comor-
bidities explain why patients in the IMRT group received
Table 3 Acute and late toxicity according to the type of radiotherapy (3D-CRT vs. IMRT/Tomotherapy)
3D-CRT IMRT/Tomotherapy
G0/G1 G2/3 G0/1 G2/3
Acute toxicity
Radiodermatitis 2 (5.4%) 35 (94.6%) 25 (36.8%) 43 (63.2%)
Urinary tract (dysuria) 29 (78.4%) 8 (21.6%) 55 (80.9%) 13 (19.1%)
Gastrointestinal (diarrhea) 12 (32.4%) 25 (67.6%) 36 (52.9%) 32 (47.1%)
Genital tract [female] (colpitis) 27 (73.0%) 10 (27.0%) 51 (75.0%) 17 (25.0%)
Late toxicity
Urinary tract (dysuria) 36 (97.3%) 1 (2.7%) 66 (97.1%) 2 (2.9%)
Gastrointestinal (incontinence) 35 (94.6%) 2 (5.4%) 68 (100%) 0
Genital tract [female] (atrophy of vaginal mucosa) 31 (83.8%) 6 (16.2%) 57 (83.8%) 11 (16.2%)
Genital tract [male] (impotence) 37 (100%) 0 68 (100%) 0
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67.6%,, p = 0.02). In contrast, when only looking at the
standard-chemoradiation cohort the trend towards a bet-
ter OS in the IMRT/Tomotherapy group is much less
pronounced.
It is interesting to note, that men showed a trend to-
wards a worse OS (2-year 63.5% vs. 89.5%; p = 0.05) in
multivariate analysis. Similar results could be found by
the long-term update of RTOG 98–11 (p = 0.03) [5]. A
significantly better OS at 2 years was observed regarding
patients younger than 60 years (p = 0.03). Assuming that
prevalence of human papillomavirus (HPV) infection in
women decreases with increasing age [18], a relation be-
tween HPV status and outcome can be suggested similar
to observations in other tumour entitites e.g. in oropha-
ryngeal cancer [19]. Furthermore patients with cancer of
the anal margin and patients receiving concurrent cetux-
imab showed worse median OS and PFS than the cohort
of patients with anal canal tumours treated with stand-
ard chemoradiation (24.1 and 15.7 months, 26.8 and
15.5. months vs. 48.0 and 41.2 months). In almost half
of the patients (50% and 40%) progressive disease was
observed during follow-up, usually within the first two
years. Even though interpretation is quite problematic
due to small subgroups, especially the role of cetuximab
should be discussed. A high surface expression of Epi-
dermal Growth Factor Receptor (EGFR) and low rates of
EGFR and k-ras mutations seem to enable the use of
cetuximab for anal cancer treatment [20], but only a
couple of studies describe a small benefit regarding pal-
liative treatment of anal cancer patients [21,22]. In ac-
cordance with findings from the treatment of metastatic
colorectal or head and neck cancer patients, Lukan et al.
observed a PR in 3 of 7 patients with metastatic anal
cancer and k-ras wildtype [23]. To the author’s know-
ledge no positive data exist regarding the use of cetuxi-
mab in a curative setting. One phase I trial and one
phase II trial of patients with locally advanced analcancer receiving 5-FU, cisplatin, cetuximab and radio-
therapy reported inhomogeneous efficacy and a ex-
tremely high number of serious adverse effects (SAEs)
[24,25]. Further studies in large population are required
to identify the prognostic role of cetuximab and the in-
fluence of HPV and other biomarkers.
We found similar 3-year PFS (66.5% vs. 66.5%; p =
0.88) and LC (78.3% vs. 75.3%; p > 0.99) in the 3D-CRT
group compared with the IMRT/Tomotherapy group. It
is not completely understood, why 3-year PFS ended up
being worse than those results presented by some other
studies. PFS of 72.5% (3D-CRT) and 82.3% (IMRT) at
3 years has been reported by Chuong et al. e.g. [26]. Fol-
low up in our cohort showed a relatively large propor-
tion (31.4%) of PD compared with published data with
values around 20% [15,16,27]. No difference could be
found regarding patient, tumour or treatment character-
istics except for a large number of tumour grading ≥ 3
(31.4%) in comparison with the literature. No statistically
significant difference between the two radiation tech-
nique groups was found regarding CFS (p = 0.48). 3-year
CFS rate of 87.9% in our cohort is comparable with find-
ings from other studies showed 3-year CFS ranging from
86% to 91.3%/93.7% [13,26].
Several studies suggested decreased toxicity rates by
using modern radiation techniques like IMRT [13,26].
These data were confirmed in our cohort considering
both acute and late toxicity. In general no grade 4 acute
or late adverse effects were observed. Severe (G2/3) der-
matologic toxicity rate in the IMRT/Tomotherapy group
was significantly lower than in the 3D-CRT group (63.2%
vs. 94.6%; p < 0.001). Furthermore we recorded a signifi-
cantly increased proportion of severe acute gastrointes-
tinal toxicity in our cohort of 3D-CRT patients (67.6% vs.
47.1%; p = 0.03). Several studies generated similar results.
While RTOG 98–11 showed an incidence of just under
50% for grade ≥ 3 skin toxicity using 2D-RT [28], Bazan
et al. reported a significantly lower rate of grade 3 acute
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group (21% vs. 41%) [13]. In the same study grade ≥ 3
gastrointestinal toxicity was 29% and 7% in patients
treated with 3D-CRT and IMRT [13]. No significant dif-
ference was observed regarding acute genitourinary tox-
icity in both groups. Although late adverse effects were
present in our cohort, the number of events was small in
general. 16.2% of the 3D-CRT and IMRT/Tomotherapy
group developed moderate symptoms regarding to geni-
tal tract. Only one G3 genital toxicity in the 3D-CRT
group and no G3 dysuria was observed. Similar results
were reported by Kim et al. with no grade 3 or 4 late tox-
icities and an urinary incontinence rate of 2.7% [29]. 3 of
4 patients (75%) with faecal incontinence in the current
study underwent local excision before chemoradiation.
Only 12.0% in the surgery group showed T3 or T4 cancer
(T1: 40.0%) compared with 35.0% in the non-surgery
group (T1: 12.5%) - making a direct influence of the
tumour size highly unlikely whereas surgery-related mor-
bidity has to be considered when judging late gastrointes-
tinal toxicity after chemoradiation. The current study has
a number of limitations the most considerable being its
retrospective nature. Disparities in patient distribution
and a variable length of follow-up should be mentioned.
On the other hand median follow-up of 41.4 months and
the large cohort of 105 patients compared with similar
reports is one of the strengths of our study. The results
suggest that using IMRT technique severe acute toxicity
of skin and gastrointestinal tract can be reduced while
maintaining satisfactory results in disease control. How-
ever further analysis should be done evaluating the role
of HPV and cetuximab regarding treatment outcome.Conclusion
This analysis demonstrates that concurrent chemother-
apy and radiotherapy is the preferred standard of care
for anal cancer patients. The use of IMRT/Tomotherapy
is associated with less severe acute skin and gastrointes-
tinal toxicity, but no benefit could be determined regard-
ing OS, PFS, LC and CFS. Further analysis is necessary
to identify additional markers in order to improve local
control and PFS by escalating cancer treatment for se-
lected patients.
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